Rahul Banerjee, Assistant Professor at the Fred Hutchinson Cancer Center and at the University of Washington, shared a post on X about a paper he co-authored with colleagues, published in the American Journal of Hematology:
“Thanks, Larry (and all co-authors), and the American Journal of Hematology for this!
RW data for a frequent q in my own MM clinic, namely patients starting teclistamab, disappointed by D30 results after hearing ‘Median time to 1st response 1.1 mo…’
Can we predict delayed response conversion?
Yes, fairly easily, as it turns out.
- If MR at D30, keep calm and carry on.
- If SD at D30, normal ALC at that time point (but not earlier) predicts delayed responses.
- If PD at D30, subsequent response is unlikely.
DOR for early vs delayed teclistamab response is identical!
This adds to many intriguing studies around ALC and bsAbs in MM.
ALC always dips around ~ Day 7 (another reason for caution right before leukapheresis), but – if it recovers by D30 – more likely for continued bsAbs to lead to a response.
I’ve used this in the clinic already!”
Title: Predictors of Delayed Responses to Teclistamab in Multiple Myeloma After Initial Non-Response
Authors: Rahul Banerjee, Gurbakhash Kaur, Beatrice M. Razzo, Andrew J. Portuguese, Surbhi Sidana, Tiffany Richards, Ariel Grajales-Cruz, Shambavi Richard, Leyla Shune, Jack Khouri, Danai Dima, Hans C. Lee, Krina K. Patel, Oren Pasvolsky, Mariola Vazquez-Martinez, Doris K. Hansen, Aimaz Afrough, James A. Davis, Hamza Hashmi, Shebli Atrash, Christopher J. Ferreri, Kelley L. Julian, Megan M. Herr, Shonali Midha, Patrick Costello, Peter Forsberg, Andre de Menezes Silva Corraes, Yi Lin, Andrew J. Cowan, Larry D. Anderson Jr, Alfred L. Garfall
You can read the Full Article in the American Journal of Hematology.
More posts featuring Rahul Banerjee.
